[go: up one dir, main page]

WO2007047653A3 - Analogues peptidiques de liaison synthetiques hla d'une enzyme v617f jak2 mutante et leurs utilisations - Google Patents

Analogues peptidiques de liaison synthetiques hla d'une enzyme v617f jak2 mutante et leurs utilisations Download PDF

Info

Publication number
WO2007047653A3
WO2007047653A3 PCT/US2006/040517 US2006040517W WO2007047653A3 WO 2007047653 A3 WO2007047653 A3 WO 2007047653A3 US 2006040517 W US2006040517 W US 2006040517W WO 2007047653 A3 WO2007047653 A3 WO 2007047653A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutant
binding peptide
peptide analogues
uses therefor
hla binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040517
Other languages
English (en)
Other versions
WO2007047653A2 (fr
Inventor
David A Scheinberg
Rena J May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2007047653A2 publication Critical patent/WO2007047653A2/fr
Publication of WO2007047653A3 publication Critical patent/WO2007047653A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des peptides synthétiques comprenant au moins des analogues d'un peptide mutant V617F JAK2 qui se lie spécifiquement à des molécules HLA de classe I ou de classe II sur une caractéristique cellulaire d'un trouble myéloprolifératif ou d'une maladie myéloproliférative, chez un patient. L'invention concerne des compositions pharmaceutiques et des compositions immunogéniques comprenant au moins lesdits segments analogues peptidiques ou un ADN codant ceux-ci. L'invention concerne encore des méthodes d'utilisation de ces peptides synthétiques et de ces compositions immunogéniques, lesquelles méthodes étant destinées à induire une réponse immunitaire hétéroclitique ou à traiter un trouble myéloprolifératif ou une maladie myéloproliférative.
PCT/US2006/040517 2005-10-17 2006-10-17 Analogues peptidiques de liaison synthetiques hla d'une enzyme v617f jak2 mutante et leurs utilisations Ceased WO2007047653A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72757805P 2005-10-17 2005-10-17
US60/727,578 2005-10-17

Publications (2)

Publication Number Publication Date
WO2007047653A2 WO2007047653A2 (fr) 2007-04-26
WO2007047653A3 true WO2007047653A3 (fr) 2007-09-27

Family

ID=37963204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040517 Ceased WO2007047653A2 (fr) 2005-10-17 2006-10-17 Analogues peptidiques de liaison synthetiques hla d'une enzyme v617f jak2 mutante et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2007047653A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190328857A1 (en) * 2016-06-10 2019-10-31 Io Biotech Aps Calr and jak2 vaccine compositions
JP7630507B2 (ja) 2019-11-18 2025-02-17 ヤンセン バイオテツク，インコーポレーテツド 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (fr) 2020-12-21 2022-06-30 Incyte Corporation Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
JP2025500258A (ja) * 2021-12-16 2025-01-09 ヤンセン バイオテツク，インコーポレーテツド 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
EP4493558A1 (fr) 2022-03-17 2025-01-22 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de jak2 v617f

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMIESON C.H.M. ET AL.: "The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation", PROC. NATL. ACAD. SCI., vol. 103, no. 16, April 2006 (2006-04-01), pages 6224 - 6229 *

Also Published As

Publication number Publication date
WO2007047653A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2005053618A3 (fr) Analogues peptidiques synthetiques de liaison a l'antigene histocompatibilite et leurs utilisations
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
UA97095C2 (ru) Противораковая вакцина, которая содержит опухолевоассоциированный пептид, который связывается с молекулами лейкоцитарного антигена человека (hla) класса i или ii, и ее применение в производстве лекарственного средства
WO2006082406A3 (fr) Proteines et anticorps humains
WO2007104062A8 (fr) Compositions et procédés concernant le profilage d'une pluralité de lignées cellulaires en fonction de leur liaison à des peptides
WO2007047653A3 (fr) Analogues peptidiques de liaison synthetiques hla d'une enzyme v617f jak2 mutante et leurs utilisations
GEP20105059B (en) Anti-cd154 antibodies
WO2004067023A3 (fr) Peptides derives de la survivine et leur utilisation
WO2004078778A3 (fr) Peptides presentant une fixation specifique avec le recepteur de hgf (cmet) et ses utilisations
WO2006060314A3 (fr) Generation de virus capables de replication a usage therapeutique
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
WO2007002373A3 (fr) Utilisation de l'herpes simplex virus type 2 mutant dans le traitement du cancer
UA94221C2 (en) Lipocalin protein
WO2007058942A3 (fr) Imidazopyrazines inhibant la proteine kinase
WO2006037421A3 (fr) Epitopes de lymphocytes t auxiliaires immunogenes provenant d'antigenes tumoraux humains et procedes immunotherapeutiques utilisant ces epitopes
WO2005113601A8 (fr) Anticorps et molecules derivees de ceux-ci se liant aux proteines steap-1
WO2006112930A3 (fr) Sparc mutant a deletion q3 et utilisations dudit polypeptide mutant
WO2007014001A3 (fr) Determination multiplexee de fragments de fixation specifiques aux lipides
WO2008113515A3 (fr) Antagonistes sélectifs de hutnfr1
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
WO2007044809A3 (fr) Préparations pharmaceutiques basées sur une toxine botulique sans albumine et contenant une hyaluronidase, et méthodes d'emploi
WO2007025760A3 (fr) Oligopeptides associes au complexe d'histocompatibilite principale (mhc) de classe i, associes au melanome et leurs utilisations
WO2008080091A3 (fr) Activation du chemin rig-i
WO2005009366A3 (fr) Restauration d'une fonction vasculaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06826095

Country of ref document: EP

Kind code of ref document: A2